Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer (sncRNA)
The purpose of this study is to create new tests to identify biomarkers for ovarian cancer so that a screening test can be developed. For patients who have a diagnosis of ovarian Cancer, researchers will use blood samples before and after treatment to see if disease status can be determined by measuring the amount of biomarker.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer|
- Defining sncRNA alterations associated with hereditary predisposition to ovarian cancer [ Time Frame: 24 months ] [ Designated as safety issue: No ]Serum samples will be collected from patients with known BRCA mutations. As a control, we will recruit age-matched women undergoing gynecologic evaluation for benign disease without any personal or family history of cancer. The normal and BRCA mutation groups will be pooled for deep sequencing. Pooled sample short RNAs will be cloned and subjected to deep sequencing and bioinformatic analysis. Validation of 5-10 differentially expressed sncRNAs is performed by quantitative RT-PCR and Northern blots on individual control and high risk samples.
- Identification of serum derived sncRNA biomarkers that correlate with disease burden in ovarian cancer. [ Time Frame: 24 months ] [ Designated as safety issue: No ]In this aim pre- and post-remission samples from twenty women with stage III-IV ovarian cancer will be compared to twenty samples from control cancer-free subjects. Methods used will be essentially identical to those described above however, given the opportunity to use each patient as her own control and thus minimized confounders we believe deep sequencing of samples individually will provide better quality data and more robust statistical comparison.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Women at average risk for ovarian cancer
Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
Women with ovarian cancer
Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
Increased risk for ovarian cancer
Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
Epithelial ovarian cancer is the most lethal female reproductive malignancy, mainly because 80% of tumors have metastasized beyond the ovary at the time of diagnosis. Screening efforts aimed at improved identification of early stage disease have been largely unsuccessful, because of ovarian cancer's propensity for early spread. Our hypothesis is that this obstacle can be circumvented by identifying biomarkers for the precancerous stage of this disease. Since this pre-cancerous stage is currently undetectable, we instead propose to look for biomarkers in women at very high risk for developing ovarian cancer due to genetic mutations. We hypothesize that identification of markers for genetic predisposition to ovarian cancer will also be informative for detection of biological changes that over time lead to sporadic cancers. Given their increasingly recognized role in states of normal and abnormal growth and differentiation, we hypothesize that short non-coding RNAs (sncRNAs) hold significant promise as biomarkers of ovarian cancer predisposition. We will test these hypotheses in two aims. First, we will identify biomarkers for hereditary ovarian cancer risk by comparing serum-derived sncRNAs in women with and without hereditary risk for ovarian cancer. In the second aim we will define serum-derived sncRNAs correlates of ovarian cancer disease status. We will compare sera from ovarian cancer patients at times of highest and lowest disease burden to those of control, cancer-free subjects. Each aim will provide independent, novel, and important information for future investigations. The sncRNAs found to be differentially expressed in both aims will be prioritized for future validation in women under clinical surveillance for hereditary risk of ovarian cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01187602
|Contact: Susan Modesitt, MDemail@example.com|
|Contact: Heather L Lothamer, MSNfirstname.lastname@example.org|
|United States, Virginia|
|University of Virginia||Recruiting|
|Charlottesville, Virginia, United States, 22908|
|Contact: Heather Lothamer, MSN 434-924-9924 email@example.com|
|Contact: Susan Modesitt, MD 434-243-5197|
|Principal Investigator: Susan Modesitt, MD|
|Principal Investigator:||Susan Modesitt, MD||University of Virginia|